CRISPR Therapeutics AG (CRSP) EBIT Margin (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted EBIT Margin of 8933.33% for Q1 2026, up 50.13% sequentially from 17912.5% in Q4 2025, and up 822551.0% YoY from N/an in Q1 2025.
CRISPR Therapeutics AG (CRSP) EBIT Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported EBIT Margin for 11 years, with the latest figure at 8933.33% in Q1 2026.
- Quarterly EBIT Margin rose 822551.0% year-over-year to 8933.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15754.2% (down 1449501.0% YoY) and the FY2025 annual result came in at 18933.65%, down 1768327.0% from the prior year.
- EBIT Margin advanced to 8933.33% in Q1 2026 per CRSP's latest filing, from 17912.5% in the prior quarter.
- Over five years, EBIT Margin peaked at 34.58% in Q4 2023 and troughed at 2192350.0% in Q4 2022.
- A 5-year average of 167590.53% and a median of 18103.26% in 2024 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin slumped 219122047 bps in 2022, then soared 219238458 bps in 2023.
- Over 5 years, EBIT Margin stood at 2192350.0% in 2022, then jumped by 100 bps to 34.58% in 2023, then slumped by 623 bps to 180.96% in 2024, then tumbled by 9798 bps to 17912.5% in 2025, then soared by 50 bps to 8933.33% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 8933.33%, 17912.5%, and 14854.78% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -1,151.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,151.84% |
| Mar 31, 2026 | -8,933.33% |
| Dec 31, 2025 | -17,912.50% |
| Sep 30, 2025 | -14,854.78% |
| Jun 30, 2025 | -25,708.97% |
| Mar 31, 2025 | -17,158.84% |
| Dec 31, 2024 | -180.96% |
| Sep 30, 2024 | -18,294.02% |
| Jun 30, 2024 | -29,257.25% |
| Mar 31, 2024 | -27,894.25% |
| Dec 31, 2023 | 34.58% |
| Jun 30, 2023 | -136.03% |
| Mar 31, 2023 | -64.49% |
| Dec 31, 2022 | -2,192,350.00% |
| Sep 30, 2022 | -194,029.79% |
| Jun 30, 2022 | -115,987.34% |
| Mar 31, 2022 | -18,720.43% |
| Dec 31, 2021 | -1,129.53% |
| Sep 30, 2021 | -15,637.01% |
| Jun 30, 2021 | 84.67% |